Hierarchical models are common in complex surveys, psychometric applications, as well as agricultural and biomedical applications, to name but a few. The context of interest here is meta-analysis, with emphasis on the use of such an approach in the evaluation of surrogate endpoints in randomized clinical trials. The methodology rests on the ability to replicate the e ect of treatment on both the true endpoint, as well as the candidate surrogate endpoint, across a number of trials. However, while a meta-analysis of clinical trials in the same indication seems the natural hierarchical structure, some authors have considered center or country as the unit, either because no meta-analytic data were available or because, even when available, they might not allow for a su cient level of replication. This leaves us with two important, related questions. First, how sensible is it to replace one level of replication by another one? Second, what are the consequences when a truly three-or higher-level model (e.g., trial, center, patient) is replaced by a coarser two-level structure (either trial and patient or center and patient). The same or similar questions may occur in a number of di erent settings, as soon as interest is placed on the validity of a conclusion at a certain level of the hierarchy, such as in sociological or genetic studies. Using the framework of normally distributed endpoints, these questions will be studied, using both analytic calculation as well as Monte Carlo simulation.
Introduction
In applied sciences, one is often confronted with the collection of correlated data. This generic term embraces a multitude of data structures, such as multivariate observations, clustered data, repeated measurements, longitudinal data, and spatially correlated data. Instances of this type of research can be encountered in virtually every empirical branch of science. Di erent areas of research will refer to the same or similar concepts with di erent terminology. For example, multilevel modeling (Goldstein, 1995) is a frequently encountered term in sociological applications, whereas in classical experimental design research one often refers to variance component models (Searle et al., 1992) .
A hierarchical structure can consist of more than two levels and examples also abound in practice. Schooling systems, for instance, present an obvious multilevel structure, with pupils grouped into classrooms, which are nested within schools which themselves may be clustered within education authorities. Often in sample surveys, for cost-related reasons or administrative considerations, multistage sampling schemes are adopted. In multistage sampling, the sample is selected in stages, with the sampling units at each stage being sub-sampled from the larger units drawn at the previous stage. Thus, it immediately becomes apparent that a sample obtained by multistage sampling is hierarchical in nature and, therefore, we need to analyze such data using appropriate hierarchical techniques.
Sometimes, not only the design is hierarchical, but in addition, the formulation of the research question involves a particular level of such a hierarchy. There might then be clear dangers associated to misspecifying the hierarchical structure.
In surrogate marker evaluation, one may be interested in association between the true endpoint and the surrogate endpoints at di erent levels (individual-level and trial-level) but on the one hand data may have more than two levels while on the other hand one may have to resort to an alternative for the level of trial if not enough trial-level replication is at hand. This particular problem has motivated this research.
The aim of this paper is to evaluate the performance of di erent modelling strategies which allow us to tackle the problems described above. An overview of the methodological steps that have led to the multi-level setup in surrogate marker evaluation is given in Section 2. Two clinical studies in schizophrenia, where di erent units of analysis can be considered, are introduced in Section 2.1. An alternative area of application is found in survey research. Data from the Belgian Health Interview Survey are described in Section 3. The meta-analytic setting, to be used throughout the paper, is introduced in Section 4. The di erent analytic approaches are presented in Section 5. A simulation study is reported in Section 6. With the results of the simulation study in mind, the data are analyzed in Section 7.
Surrogate marker validation
Surrogate endpoints are referred to as endpoints that can replace or supplement other endpoints in the evaluation of experimental treatments or other interventions.
For example, surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the endpoints of interest, which are referred to as the "true" endpoints (Ellenberg and Hamilton, 1989) . Prentice (1989) proposed a formal deÿnition of surrogate endpoints and outlined how potential surrogate endpoints could be validated. Buyse et al. (2000) suggested the use of combined evidence from several clinical trials, such as in a meta-analysis, rather than from a single study. To this end, they needed to formulate a bivariate hierarchical model, accommodating the surrogate and true endpoints in a multi-trial setting.
Of course, the switch to a meta-analytic framework does not solve all problems surrounding surrogate marker validation in a deÿnitive way. A result of the change to meta-analysis is that computationally rather involved statistical models have to be used. For the case of surrogates and true endpoints that are both normally distributed, Buyse et al. (2000) employed linear mixed-e ects models (Verbeke and Molenberghs, 2000) . Even in this case, which from a statistical modeling point of view can be considered a basic one, ÿtting such linear mixed models turns out to be surprisingly di cult. Tibaldi et al. (2003) carefully studied this computationally-oriented issue. They have investigated several simpliÿed strategies to deal with the computational burden posed by using such hierarchical linear models, primarily in the context of validating surrogate markers. These strategies are ordered following three choices: (1) whether trial-speciÿc parameters are treated as random or ÿxed, (2) whether the endpoints are treated as correlated or not (bivariate versus univariate) and (3) the method of dealing with measurement error. As a result of their investigation, they recommend simpliÿed computational methods for two main reasons. First, the methods are generally faster and easier to implement with standard software. Second, Tibaldi et al. (2003) showed, through simulations, that the simpliÿed approaches often perform almost as good as the more advanced methods, and moreover enjoy much better convergence properties. As a cautionary remark, it needs to be emphasized that these results were derived in the context of normally distributed endpoints. Di erent types of outcomes (e.g., of a generalized linear type) may lead to a somewhat di erent picture (see., for example Xiang et al., 2002; Concordet and Nunez, 2002) .
Very important issues arise from the choice of levels within such a hierarchical analysis. Indeed, while perhaps the most natural choice seems to be the one of trial, in practice, other units have been used in the validation process. Indeed, several authors have made alternative choices for reasons of convenience which then leaves us with the question of whether such particular unit will provide us with a good representation of what is happening at the targeted trial level. For example, Buyse et al. (2000) , Burzykowski et al. (2001) , and Alonso et al. (2002) considered a number of case studies, using either center or country as unit of analysis, rather than trial. Given that the construction of the trial-level surrogacy hinges on the choice of independent unit which preferably is trial, it is necessary to study the impact of deviations of such a choice. There are two broad classes of deviations from such an approach. First, as was done in some of the works cited earlier, some authors change from trial to center, country, or investigator, for reasons of convenience. Indeed, one may have higher number of replication over such alternative units than over trial. Second, the true data generating mechanism can and will often be hierarchical with more than two levels, such as patients within centers and at the same time centers within trials. The impact of such deviations on the study result are important and will be considered here in terms of their statistical and numerical properties. Analytic considerations are supplemented with results from small sample simulations and illustrated using data from two clinical trials in schizophrenic patients.
Clinical studies in schizophrenia
The ÿrst of the two psychiatric studies in schizophrenic patients is based on a meta-analysis containing only ÿve trials. This is insu cient to apply the meta-analytic methods. In all of the trials, information is also available on the investigators which treated the patients. Thus, we can also use investigator as the unit of analysis. For this case a total of 138 units are available for analysis, with the number of patients per unit ranging from 2 to 30. The true endpoint is Clinician's Global Impression (CGI). This is a 7-grade scale used by the treating physician to characterize how well a subject is doing. As a surrogate measure, we consider the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1988) . The PANSS consists of 30 items that provide an operationalized, drug-sensitive instrument, which is highly useful for both typological and dimensional assessment of schizophrenia. Table 1 shows the frequency of unit-speciÿc sample sizes. Clearly, the majority of units consists of less than 5 patients.
Alternatively, one could also consider the main investigator as unit of analysis. For 4 out of the 5 trials, only one main investigator was used leading to extremely large investigator sites. This leads to a total number of 29 units with the number of patients per unit ranging from 4 to 450, 4 of which represent trials. Another possibility is to consider the countries where patients were treated, which fortunately is also available. Hence, we can also use country within trial as the unit of analysis. In this case a total of 19 units are available, with the number of patients per unit ranging from 9 to 128. The comparison of the three di erent choices will be used as an empirical assessment as to the importance the choice of unit can have on the results.
In addition, we will use data from an international equivalence trial (INT-10) on schizophrenic patients (Nair and the Risperidone Study Group, 1998) . The trial included 206 schizophrenic patients. All patients received an equal daily amount of risperidone during 8 weeks, but 103 patients were randomized to a one-time daily intake (O.D.), while the remaining 103 patients were randomized to receive risperidone twice a day (B.I.D.). The surrogate and true endpoints are again PANNS and CGI, respectively. We will consider the investigator as the unit of analysis. This leads to a total of 34 units available for analysis with the number of patients per unit ranging from 2 to 15.
The Belgian Health Interview Survey
In 1997, the second Belgian Health Interview Survey took place (HIS1997). The HIS1997 was conducted to evaluate the usefulness of a periodic health-related survey, with the idea to collect information on the subjective health of the Belgian population, as well as on important predictor variables.
The survey is still ongoing (the second one took place in 2001) and the main goal of the HIS is to give a description of the health status of the overall population in Belgium as well as of the three regional subpopulations (Flemish, Walloon and Brussels region), and in addition of the German community.
The total number of successful interviews for the sample in the HIS1997 was set to 10,000. The sampling of the households and respondents is a combination of several sampling techniques: stratiÿcation, multistage sampling and clustering, and di erential selection probabilities. The sampling of respondents took place in the following steps: (1) stratiÿcation by region and province, (2) selection of the municipalities within each stratum, (3) selection of a cluster of households within each municipality and (4) selection of respondents within a household. Such a multi-stage design with municipalities as primary selection units is a feasible solution.
Second-and third-stage selection units are households within municipalities and individuals within households, respectively. Municipalities are established administrative units. They are stable (in general they do not change during the time the survey is conducted) and they are easy to use in comparison with other specialized sources of data related to the survey. Municipalities are preferred above regions or provinces, because the latter are too large and too few. The large variation in the size of the municipalities is controlled for by systematically sampling within a province with a selection probability proportional to their size.
The three-level hierarchy encountered here, is simpler than the one in surrogate marker evaluation, where we have two endpoints (surrogate and true), and hence a pair of three-level structures. Strictly speaking, the latter situation could therefore be seen as a four-level structure.
Model description and setting
In this section, we will introduce a three-level model for normally distributed endpoints. This model will allow us to consider the fully general case of a three-way hierarchy (e.g., patients within centers and centers within trials), as well as sub-cases that are of a two-level type. The emphasis will be on the surrogate marker situation, where such a model is needed for both the surrogate as well as the true endpoint. For cases such as the Health Interview Survey, the setting simpliÿes to just one hierarchical model. At the same time, the impact of misspeciÿcation by modelling the data as if they arose from a two-way structure, even though they were generated under a three-way model, can be assessed. In addition, the impact of considering the sub-unit e ects as ÿxed, even though they are generated using a random-e ects model, is studied. Let T ijk and S ijk be random variables denoting the true and the surrogate endpoints for subject k = 1; : : : ; n ij in center j = 1; : : : ; N i within trial i = 1; : : : ; M . Further, let Z ijk denote a binary treatment indicator. The full three-way random-e ects model, as it was introduced by Buyse et al. (2000) for the two-way hierarchy, can the be written as
where S and T are ÿxed intercepts, m Si and m Ti are random intercepts for trial i, and m Sij and m Tij are random intercepts for center j in trial i. The parameters and ÿ are ÿxed treatment e ects, a i and b i are random treatment e ects associated with trial and a ij and b ij are random treatment e ects related to center. The individual-speciÿc error terms are S ijk and T ijk . The vector of random e ects associated with trial, (m Si ; m Ti ; a i ; b i ) T , is assumed to be zero-mean normally distributed with variance-covariance matrix
The vector of random e ects associated with center, (m Sij ; m Tij ; a ij ; b ij ) T , is also assumed to be zero-mean normally distributed with variance-covariance matrix
Finally, the individual-level error terms ( S ijk ; T ijk ) T are also zero-mean normally distributed with variance-covariance matrix
Parameter estimation can be based on, for example, maximum likelihood or restricted maximum likelihood (Verbeke and Molenberghs, 2000) . Several authors, cited in the introduction, have employed this strategy. Clearly, (1) is not free from modeling assumptions. For example, one might want to entertain ÿxed e ects rather than random e ects. This will be considered in Section 5, where the second strategy would then be very appropriate. Indeed, ÿtting a random-e ects model in such a case might lead to incorrectly attributing components of variability. Further, the joint normality of (1) implies that the regression of T ijk on S ijk is linear, whereas in reality a nonlinear association might apply. In practice, therefore, one may want to carefully assess the ÿt of the model. For the purpose of this article, model (1) is considered a versatile paradigm.
In the remainder of the section, we will brie y sketch the use of these models in surrogate marker validation. Of course, this is not relevant for the HIS example. The next step considered in the methodology proposed by Buyse et al. (2000) focused on prediction. Precisely, assuming one considers a new trial, i = 0 say, for which data are available on the surrogate endpoint but not on the true endpoint, the goal is to predict the outcome on the true endpoint. We are interested in the estimated e ect of treatment Z on true endpoint T , given the e ect of Z on the surrogate S for this particular trial. Let us subscript all quantities pertaining to the particular trial under study with 0.
It is easy to show (Buyse et al., 2000) that (ÿ + b 0 |m S0 ; a 0 ) follows a normal distribution with mean and variance:
Related to prediction equations (5)- (6), a measure to assess the quality of the surrogate at the trial level, as it was stated by Buyse et al. (2000) , is the coe cient of determination
Similarly, to measure individual-level surrogacy, Buyse et al. (2000) proposed to use the coe cient of determination given by
where ST , SS and TT are components of variance-covariance matrix (4). As Buyse et al. (2000) posed, R 2 trial (f ) = 1 and R 2 indiv = 1 indicate perfect surrogacy at the trial and individual level, respectively. Realistically, one could call a surrogate 'good' at a certain level, if the corresponding R 2 is su ciently close to one. Of course, this is not just a statistical matter but rather a combination of statistical and substantive considerations.
Intuition can be gained by considering the simpliÿed case where the prediction of ÿ + b 0 is done independently of the random intercept m S0 . Coe cient (7) then reduces to
which is simply the square of the correlation coe cient for a i and b i . This formula is useful when the full random-e ects model is hard to ÿt but a reduced version, excluding random intercepts, is easier to reach convergence. It is simply the square of the correlation between a i and b i . Note that R 2 trail (r) = 1 if the trial-level treatment e ects are simply multiples of each other.
In our three-level context, the same procedure can be followed for the center level and R 2 center (r) and R 2 center (f ) can be computed a way similar to (7) and (9) using matrix (3), providing us with an assessment of the center-level surrogacy. Tibaldi et al. (2003) showed that, in the two-level hierarchy, ÿtting random-e ects model (1) can be replaced by simpliÿed computational methods. In the remainder of this paper simpliÿed methods will be used to face the computational challenges. In particular, we consider three strategies:
Modeling strategies
Strategy I: Two-Level Only. This pertains to the case where, in spite of the threelevel data generating mechanism, we consider either the trial level or center level for analysis and for validation, but not both. The trial and center-speciÿc e ects are treated as ÿxed.
Strategy II: Three Levels, Fixed E ects. A model in which the full three-level structure of the data is included. Both the trial-speciÿc and the center-speciÿc e ects are treated as ÿxed.
Strategy III: Three Levels, Random E ects. A model in which the full three-level structure of the data is included. Both the trial-speciÿc and center-speciÿc e ects are treated as random.
We will now discuss each of these three strategies in turn.
Strategy I: two-level only
Here again, we will put emphasis on the surrogate marker evaluation context, the Health Interview Survey context being a simpliÿcation of this one. As stated before, the parameters of the full random-e ects model (1) can be estimated by maximum likelihood or restricted maximum likelihood, using standard linear mixed model software such as the SAS procedure MIXED (Verbeke and Molenberghs, 2000) .
Trial level only
In case we only consider the trial level for the validation process, exactly as Tibaldi et al. (2003) , we can rewrite and simplify the model as
where Si , Ti , i , and ÿ i are trial-speciÿc intercepts and treatment e ects. In addition, the univariate approach is opted for and hence errors ( S ijk , T ijk ) in (10) are assumed independent, rather than correlated. Tibaldi et al. (2003) showed that this approach is computationally advantageous, while resulting in little or no loss of e ciency when the emphasis is on the trial-level surrogacy. Of course, if one is interested in individual-level surrogacy as well, the correlation between the outcomes needs to be accounted for. At the second stage, a regression model is ÿtted to the treatment e ects, estimated at the ÿrst stage. For example,
As Tibaldi et al. (2003) stated, this model can then be employed to assess the trial-level surrogacy, using the R 2 trial (f ) associated with the model. The coe cient is not calculated as in (7), but it rather just is the classical coe cient of determination found by regressingÿ i onˆ Si andˆ i .
If trial-speciÿc intercept from the surrogate model (10) is not used, 1 is dropped from (11) and an R 2 trial (r) is obtained, similar in spirit to (9).
Center level only
In case we only consider the center level for the validation process, and analogous to the previous case, the model can be rewritten as
where now Sij , Tij , ij , and ÿ ij are center-speciÿc intercepts and treatment e ects. As in the previous case, the models are ÿtted separately and the errors are assumed to be independent. At the second stage, a regression model similar to (11) is ÿtted to the treatment e ects, obtained from the estimation at the ÿrst stage:
The model can be used to assess the center-level surrogacy, using the R 2 center (f ) associated with this regression. In case that center-speciÿc intercept from surrogate model is not used, a reduced R 2 center (r) is obtained.
Strategy II: three levels, ÿxed e ects
We now include both trial as well as center e ects in the ÿrst-stage model, but they are considered to be ÿxed rather than random. The model then reads
where both errors ( S ijk ; T ijk ) are to be dependent. At the second stage, an appropriate set of regressions is ÿtted to the treatment e ects, estimated at the ÿrst stage:
Model (15) is used, when the trial-level association is of interest. Model (16) is used, when the focus is on the association at the center level. Both regressions produce an R 2 measure of surrogacy.
Strategy III: three levels, random e ects
Buyse et al. (2000) assumed the availability of individual-patient data and formulated a two-stage model, with the joint distribution [T; S|Z] speciÿed at the ÿrst stage and the joint distribution of the treatment e ects [ÿ; ] speciÿed at the second stage. Shkedy et al. (2003) employed this methodology and developed a Bayesian approach under the assumption that individual data are available (see also Liao, 2002; Browne et al., 2002) . We will extend their methodology for model (1).
Generally, consider linear predictors for T and S:
The coe cients m Si , m Ti , a i , b i , m Sij , m Tij , a ij , b ij have a similar meaning as those in model (1). Further, the vector of random e ects associated to trial, (m Si ; m Ti ; a i ; b i ) T , is assumed to be zero-mean normally distributed with covariance matrix (2), while the vector of random e ects associated to center, (m Sij ; m Tij ; a ij ; b ij ) T , is assumed to be zero-mean normally distributed with covariance matrix (3). Shkedy et al. (2003) proposed to combine (17) and (2)- (3), deÿning a hierarchical Bayesian model. Thus, at the ÿrst stage of the hierarchical model we specify the following joint distribution of T ijk and S ijk :
where is given by (4).
At the second stage of the model the priors for the 'ÿxed' e ects are speciÿed:
For the precision parameters in (19) ( at) hyperprior models can be speciÿed using Gamma distributions, e.g., Â
−2 S ∼ gamma(0:001; 0:001), etc. As the hyperprior distribution for the covariance matrices D, D and , a Wishart distribution is assumed:
In order to assess the trial-level surrogacy, the coe cient of determination deÿned by (7) will be used. The center-level surrogacy can be assessed using the coe cient of determination computed from (7) with matrix D , given in (3), in place of matrix D. Finally, to measure individual-level surrogacy, the coe cient of determination given in (8) can be used.
To avoid computational problems, Buyse et al. (2000) proposed a reduced model in which the linear predictors of S and T do not include trial and center speciÿc intercepts. In the hierarchical model, the likelihood at the ÿrst stage of the model can be speciÿed by omitting the trial speciÿc random intercepts from (18). This leads to the speciÿcation
At the second stage of the model, the prior distribution the random e ects, (a i ; b i ) T , is assumed to be bivariate normal with mean 0 and covariance matrix D r . Note that the covariance matrix D r is the 2×2 lower right submatrix in (2) and is assumed to follow a Wishart distribution, D −1 r ∼ Wishart(R Dr ). Other prior and hyperprior models remain the same as in the full model. For the reduced model, the coe cient of determination, measuring the trial-level surrogacy, reduces to (9). Similar considerations can be made for (a ij ; b ij ) T , which is assumed normal with zero mean and covariance matrix D r , which is the 2 × 2 right bottom sub matrix of D deÿned in (3).
A simulation study
We studied the performance of the various strategies in terms of both point estimation, as well as precision, of R 2 trial (r) and of R 2 center (r) , by means of a simulation study. A setting, similar to the one used in Buyse et al. (2000) is adopted. 
and S = 50, T = 45, = 5, ÿ = 3. Further, the true R 2 , following from (7) and (22), is set equal to either 0:5 or 0:9 at the trial or at the center level. Thus, for both The parameter 2 equals either 0.1 or 3. For every choice of values for T , C , 2 T , 2 C and 2 , simulated datasets were obtained assuming 5, 10, 20, or 100 trials, with 10 or 100 centers per trial and with 10 or 100 subjects per center. In total, 250 datasets were simulated for each setting.
Generating Mechanisms II and III
Further, a simulation was performed in which, instead of considering model (1) to generate the data, we used a model in which we have random e ects associated to either trial or to center, but not to both of them.
The ÿrst of these, termed Mechanism II and where only trial-level random e ects are considered, is given by
Alternatively, when only random-e ects at the center level are present (Mechanism III), (1) simpliÿes to
The random vectors associated to trial and center were considered, as in Mechanism I, to follow mean-zero normal distributions: (m Si ; m Ti ; a i ; b i ) ∼ N(0; D), (m Sij ; m Tij ; a ij ; b ij ) ∼ N(0; D ). Fig. 1 . Simulation study. The estimation of R 2 and its precision for R 2 trial (r) = R 2 center (r) and 2 T = 2 C = 10. Data were generated using Mechanism I. Left column: Strategy I (Two-level only); right column: Strategy II (Three-levels, ÿxed e ects). Top row: estimation of R 2 = 0:5; bottom row: estimation of R 2 = 0:9.
A setting of simulation parameters similar to the one used for Mechanism I was considered, i.e., 5, 10, 20 or 100 trials, with 10 or 100 centers and 10 or 100 subjects per center; 1 shows the results obtained when Strategies I and II were used. In particular, the use of Strategy I means, that the association at the trial level was evaluated using a model without the center level (see (10) in Section 5.1.1), while the association at the center level was assessed using a model without the trial level (see (12) in Section 5.1.2). Fig. 1 indicates that both strategies give comparable results. It can be observed that Strategy II has larger bias in the estimation than Strategy I. It is important to point out that when 
When only one level of association is present in the data generating mechanism, we can try to estimate the e ects at this particular level using Strategy I, with either the correct or the incorrect level included in the model. That is, if Mechanism II was used, which involved only the trial-level association, we could try to capture this association using center as the unit of analysis. A similar approach could be used for Mechanism III, but in this case the center-level association could be evaluated using trial as the unit of analysis. This would correspond to realistic situations where our interest lies at another level than at which data are available from. For example, the ÿrst scenario (Mechanism II with center as the unit of analysis) is of practical interest when there are too few trials available and, to assess the trial-level surrogacy, data for centers is used instead. The results for 5, 10 or 20 trials with 10 centers per trial and 10 subjects per center and From Fig. 2 , it can be seen that when the data were generated using Mechanism II, the strategies proposed in Sections 5.1.1 and 5.1.2 led to very similar results. That is, the estimated strength of the (trial-level) association was similar irrespectively of whether trial (correctly) or center (incorrectly) was used as the unit of analysis. On the other hand, when Mechanism III was used to generate the data, the method described in Section 5.1.2 (i.e., using, correctly, center as the unit of analysis) performed much better than the method of Section 5.1.1. To be precise, for the analysis based on centers the estimates were closer to the true parameter. As in Section 6.2.1, when 2 T and 2 C were equal to 0.5, Strategy I tended to overestimate the strength of the association, while 2 T and 2 C were equal to 0.9, it was generally underestimated. In addition, Strategy II was also applied to the simulated datasets. In this case, ÿrst three-level ÿxed-e ects model (14) was ÿtted to the data, and then models (15) and (16) were used to compute the determination coe cients assessing the strength of association at the trial and center level, respectively. The results for 5, 10 or 20 trials with 10 centers per trial and 10 subjects per center and based on center-speciÿc estimates, the results were poor. Fig. 3 also shows that when Mechanism III was used to generate the data, Strategy II gave similar results in terms of bias irrespectively of the model used at the second stage.
Simulation results, unequal trial-and center-level association
The results of simulations presented in Section 6.2 allow to conclude that both Strategy I and Strategy II performed reasonably well when the association at the trial and at the center levels were equal. In this section we present the case in which the associations at both levels di er. Fig. 3 . Simulation study. The estimation of R 2 and its precision for Strategy II (Three-levels, ÿxed e ects) when R 2 trial (r) = R 2 center (r) and 2 T = 2 C = 10. Left column: generating Mechanism II; right column: generating Mechanism III. Top row: estimation of R 2 = 0:5; bottom row: estimation of R 2 = 0:9.
Performance of Strategies I and II
To further study the performance of Strategies I and II, we simulated data using Mechanism I, with Table 2 .
In terms of bias, the results from Table 2 are reasonable for the estimation of the trial-level association when Strategy I was applied (i.e., using trial as the unit of analysis at both stages) and of the center-level association when Strategy II was applied (i.e., Table 3 indicates that, when the variability at the center level was much smaller than at the trial level, the estimates obtained using either Strategy I or Strategy II for the trial-level association were close to the true value of the parameter of interest. On the other hand, for the center-level association, reasonable results were obtained only for Strategy II when 2 C = 0:9. For other cases using center as the unit of the analysis, either at both stages (Strategy I) or only at the second one (Strategy II), was producing results that, on average, were close to the value of the coe cient of determination related to the trial-level association.
Insights in the performance of Strategy I
The bad performance of Strategy I, especially for the center level, can be explained by the fact that ignoring a level can lead to overestimation of the variability at the levels surrounding the level being ignored. To this aim, we will use the results obtained by Hutchison and Healy (2001) . For example, consider the following model:
It is similar to model (1), but it contains only three random e ects: random intercepts m Si and m Sij associated to trial and center, respectively, and the random error S ijk . Assume that the data are balanced (N i ≡ N; n ij ≡ n) and the variances of the random e ects corresponding to the trial, center and individual level are equal to 2 T , 2 C and 2 , respectively. It can be then shown that the two variance components of the model in which the center level is ignored are:
Thus, they can be seen as the true variance, plus a certain fraction of the variance of the random e ect associated to the level that has been ignored. For this particular case not much variability is added to the variance corresponding to the level above the one ignored (trial), since most of the information is sent to the level below. This is the reason why in Tables 2 and 3 the trial-level association is generally well estimated when Strategy I is used. On the other hand, if the trial level is ignored, the center-level variance becomes
The individual-level variability remains unchanged. Thus, most of the variability contained in the trial level is sent to the center level, which a ects the estimation of the association at the center level. This is the reason why in Tables 2 and 3 the center-level association is poorly estimated when Strategy I is used.
Performance of strategy II in a large dataset
In order to further explore the behavior of Strategy II observed in Tables 2 and  3 , an additional simulation was conducted. Table 4 Simulation study Results for Strategy II for di erent values of variance components associated to trial and center random e ects, with 100 subjects per center, 100 centers per trial and 100 trials. Mean estimates of 2 T and 2 C with model-based and empirical standard errors (in parentheses).
a Gives estimates of 2 T . b Gives estimates of 2 C . 100 centers per trial and 100 subjects per center. The idea is to investigate the behavior of the strategy in a large dataset. Results presented in Table 4 indicate that, the center-level association was in general estimated reasonably well. It is worth noting that the bias, observed in Table 3 for the combination of 2 T = 0:9 and 2 C = 0:5, was greatly reduced when 2 = 3, and essentially disappeared when 2 =0:1. This suggests that, for Strategy II, the bias in the estimation of the center-level surrogacy may be negligible as long as the variability at the level of center is at least as large as the variability at the lower (individual) level.
On the other hand, from Table 4 one can see that, when the variability at the trial and center level was of the same magnitude, the trial-level association was estimated poorly, even though the sizes of the units were large. The bias generally disappeared when the variability at the center level became much smaller than that at the level of trial. This suggests that, as for the center-level association, bias in the assessment of the trial-level association for Strategy II may be negligible as long as the variability at the lower (center) level is smaller.
Comparison of strategies II and III
Finally, we attempted to compare Strategy II with Strategy III. Since using a maximum-likelihood approach to implement Strategy III was numerically too complex, we considered the use of a Bayesian approach. Unfortunately, performing an extensive simulation using the latter approach turned out to be too time-consuming. Therefore, the simulation study was limited to the random generation of only one dataset for di erent parameter settings, and the comparison of the results obtained for Strategy II Table 5 Simulation study and Strategy III to the true values of the parameters used for simulations. The results are shown in Table 5 .
By comparing the estimates of the coe cients of determination to their actual values (i.e., the values computed from the actual, simulated random e ects) in Table 5 we can observe that, when the variability at the center and trial level was of the same magnitude, Strategy II did not estimate the trial-level association well, in contrary to Strategy III. Even when the variability at the center level was smaller than that at the level of trial, estimates obtained for Strategy III were closer to the actual values than the estimates produced by Strategy II. One can conclude, admittedly based on the anecdotal evidence obtained by generating a single dataset under each setting, that Strategy III gives better results, which is reasonable if we take into account that the other two strategies are ignoring levels and are using ÿxed e ects as representation of random e ects.
Analysis of case studies

Studies in schizophrenia
In the ÿrst psychiatric study, several options were studied considering the units available. The ÿrst row in Table 6 shows the results obtained when Strategy I was applied. That is, the coe cient of determination associated to a particular level was estimated using a (two-stage) model including only this level and individual variability. We observe that, in general, there is relatively little di erence between the estimates obtained.
Strategy II, using a ÿxed-e ects model with all three levels included at the ÿrst stage, was ÿtted as well. In this model the estimate of the magnitude of the association at the highest level (country) is close to that obtained using Strategy I. For the other two levels more substantial di erences can be observed.
Finally, a random-e ects (Strategy III) analysis, based on the Bayesian approach, was performed. The results are shown in the last row of Table 6 . One can see that the estimates of the magnitude of the association for the two highest levels (main investigator and country) are lower than those obtained for the two other strategies. As for Strategy I, there is relatively little di erence in the estimates obtained for di erent levels.
Let us turn attention to the second psychiatric case study, where data from an equivalence trial are used. The result for the investigator level (R 2 = 0:70, bootstrap-based 95% C.I. [0:44; 0:96]), obtained using Strategy I, is within the range of the estimates observed for the ÿrst study (see Table 6 ). This observation supports the claim that might have been able to reasonably accurately quantify the surrogacy of PANSS for CGI in the context of certain compounds for schizophrenia. Of course, the R 2 values are not terribly high, so that a mere replacement of CGI by PANSS may be questionable. 
Belgian Health Interview Survey
We focus on log-transformed body mass index (BMI) as a normally distributed outcome. In an attempt to ÿnd a parsimonious model for these data, the following covariates were examined: sex, age (eight categories), education (ÿve categories), household income (5 categories), and smoking behavior. Note that the question about smoking behavior was addressed only to persons aged 15 or more, thus reducing the e ective sample size from 10,221 to 8560. In addition to the aforementioned covariates, information about the sample design can be taken into consideration, such as: stratiÿcation variables (quarter and provinces); size variables (province, municipality, household); number of groups to be interviewed within a municipality; and interviewee status (indicating whether he/she is the reference person or his/her partner).
Due to unit-and item non-response, 7422 out of 8560 (87%) observations were available with complete information on the selected covariates and BMI. For illustration purpose the analysis will be restricted to the province of Limburg, where 324 observations were available for the modelling procedure. The following model was ÿtted to the data:
with y ijk being the log of BMI for subject k in household j from municipality i, a i ∼ N(0; 2 MUN ), a ij ∼ N(0; 2 HH ), and ijk ∼ N(0; 2 ). Thus, the total variation in (log) BMI can be decomposed into that between individuals within each household ( 2 ), that between households within municipalities ( 2 HH ), and that between municipalities ( 2 MUN ). Among covariates listed above, only sex, age, education, and smoking behavior were found to have a signiÿcant e ect and were included in the model. Second-order interaction terms of sex with age and smoking behavior, education with smoking behavior and age, and smoking behavior with age were also included. Among sampling-related variables, only interviewee status was retained.
The 
The intra-unit correlation re ects the proportion of the total variability in the outcome variable that is attributable to the clustering e ect at a certain level and, as such, is a measure of within-group homogeneity. Table 7 shows the estimated variance and intra-class correlation coe cients associated with the household and municipality levels, obtained for model (28) ÿtted to the data using di erent modelling approaches. We will ÿrst concentrate on the ÿxed-e ects approach, i.e., treating random-e ects as ÿxed. The variance component corresponding to the random e ects at a particular level is computed as the sample variance of the estimated ÿxed-e ects at that level. The results obtained for models with one of the levels ignored show a strong disagreement with those obtained for the model with both levels included. For example, the intra-household correlation is estimated to equal 0.855 and 0.590 when municipality level is excluded or included (in addition to the household level) in the model, respectively. Clearly, such a di erence can lead to completely di erent conclusions.
For a likelihood-based random-e ects model estimation approach (such as, for example, the one implemented in the SAS procedure MIXED), the estimated variance components are smaller (column "Random" in Table 7 ). No big di erences are observed in the estimated intra-municipality and intra-household correlation when both levels are included or when one of them is ignored.
Using reasoning similar to the one leading to Eqs. (25)- (26), one can show that if we ignore the household level, the municipality and the residual variances for a balanced design become:
where N is the number of subjects per household and N HH is the number of households. This result indicates that if N ¿ 1, the resulting intra-municipality correlation will be larger than the true one. This is exactly what we observe: the intra-municipality correlation is bigger in the case where we ignore the household level. The same can be done for the model in which municipality is ignored. In this case the residual variance remains the same, but the household variance becomes equal tõ 
where N MUN is the number of municipalities. HH + 2 : Again, this is in accordance with our observation: the intra-household correlation is smaller when municipality is ignored. In our application the di erence is negligible, though, due to the fact that the variability at the municipality level is very small.
Finally, similar results for the intra-class correlation coe cients can be observed for the random-e ects Bayesian approach (column "Bayesian" in Table 7 ). In this case the results can be illustrated using the (posterior) density functions of the estimated variance components. From Fig. 4 , we can observe that, in general, when a level is ignored the densities are shifted to the right, except for the case of the residual variance when municipality was ignored. When the household level is ignored the shift to the right is bigger, and it is due to the fact that the household variance is six times larger than the municipality variance. In Fig. 5 the (posterior) densities for the correlations are plotted. It can be seen that there is almost no impact of the exclusion of a level in the estimation model on the density functions. This is due to the fact that the municipality variance is six times smaller than the household variation.
Concluding remarks
In this paper, we have investigated several strategies to deal with hierarchical linear models. We have been interested primarily in the estimation of the strength of the association between random e ects at di erent levels. This interest has been motivated in the context of validating surrogate markers.
Three di erent strategies have been considered in the paper: (1) applying ÿxed-e ects models with only the trial level or the center level used in the validation process (Strategy I); (2) including both levels in a ÿxed-e ects model at the ÿrst stage (Strategy II); and (3) including both levels in a random-e ects model at the ÿrst stage (Strategy III). The strategies di er in the complexity of the models. Consequently, they also di er in the ease of their practical implementation.
In general terms, the results indicate that the performance of the strategies depends on the sample sizes, as well as on the variablity present at di erent levels. The latter dependence, especially for Strategy I, can be explained using theoretical results on the e ect of ignoring levels when ÿtting multi-level models presented in a recent article by Hutchison and Healy (2001) .
In particular, from the conducted simulations we could conclude that, when data were generated according to a model with random e ects present at both levels, and when the strength of association between the random e ects was the same at both levels, all the strategies produced reasonable results. When the association was di erent, Strategy I, with trials as the units of analysis, produced satisfactory estimates of the trial-level association. On the other hand, using centers as the units of analysis resulted in biased estimates of the center-level association. The estimates were, in fact, close to the true value of the measure of the strength of the trial-level association, when the variability of center-speciÿc random e ects was smaller than the variability of trial-speciÿc e ects. This observation gives some justiÿcation to the use of, e.g., centers instead of trials as the units of analysis in practical applications of the meta-analytic approach to the validation of surrogate endpoints.
On the other hand, to obtain plausible estimates of the strength of the association at a particular level for Strategy II, the variability at the level below the one of interest had to be smaller.
A limited investigation of the performance of Strategy III suggested that it was able to correctly identify di erent sources of variability and association. The estimates obtained under Strategy III were closer to the actual values than, e.g., those for Strategy II. In view of the structure of the model used in Strategy III, these conclusions were not surprising. However, an important problem associated with the practical use of this strategy is its numerical complexity. From this point of view, a possibility to use, e.g., Strategy I might be very advantageous.
